-
Benitec BioPharma (BNTC) PT Lowered to $32 at H.C. Wainwright
-
Benitec's (BNTC) Capital Raise Provides Support For Regulatory Filing - Citizens
-
Benitec BioPharma (BNTC) PT Raised to $22 at Citizens After BB-301 Phase 1b/2a Study
-
Citizens JMP Reiterates Market Outperform Rating on Benitec BioPharma (BNTC)
-
Benitec Biopharma (BNTC) files $200M mixed shelf
-
Benitec Biopharma to restate quarterly financial statements
-
Citizens JMP Reiterates Market Outperform Rating on Benitec BioPharma (BNTC)
-
Citizens JMP Reiterates Market Outperform Rating on Benitec BioPharma (BNTC)
-
Benitec Biopharma gets safety board approval to advance BB-301 trial
-
TD Cowen Starts Benitec BioPharma (BNTC) at Buy
-
Citizens JMP Reiterates Market Outperform Rating on Benitec BioPharma (BNTC)
-
Benitec Biopharma (BNTC) Misses Q3 EPS by 24c
-
Benitec BioPharma (BNTC) PT Raised to $20 at Citizens JMP
-
Benitec Biopharma (BNTC) Prices $30M Share Offering at $13/sh
-
H.C. Wainwright Reiterates Buy Rating on Benitec BioPharma (BNTC)
-
Benitec Biopharma (BNTC) Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented
-
Citizens JMP Reiterates Market Outperform Rating on Benitec BioPharma (BNTC)
-
H.C. Wainwright Reiterates Buy Rating on Benitec BioPharma (BNTC)
-
Citizens JMP Reiterates Market Outperform Rating on Benitec BioPharma (BNTC)
-
Benitec Biopharma (BNTC) Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference
-
H.C. Wainwright Starts Benitec BioPharma (BNTC) at Buy
-
Baird Starts Benitec BioPharma (BNTC) at Outperform
-
Piper Sandler Reiterates Overweight Rating on Benitec BioPharma (BNTC)
-
Piper Sandler Reiterates Overweight Rating on Benitec BioPharma (BNTC)
-
Piper Sandler Reiterates Overweight Rating on Benitec BioPharma (BNTC)
-
Leerink Partners Reiterates Outperform Rating on Benitec BioPharma (BNTC)
-
Piper Sandler Reiterates Overweight Rating on Benitec BioPharma (BNTC)
-
Leerink Partners Reiterates Outperform Rating on Benitec BioPharma (BNTC)
-
Piper Sandler Reiterates Overweight Rating on Benitec BioPharma (BNTC)
-
Here's the list of biotech stocks that have key data catalysts in 2025
-
Benitec Biopharma (BNTC) Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First
-
Benitec Biopharma (BNTC) Announces Appointment of Kishen Mehta to its Board of Directors
-
Piper Sandler Starts Benitec BioPharma (BNTC) at Overweight

